Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide

Prashantha Gunaga  ^{1  2} ,  John Lloyd  ^{1  2} ,  Somanadham Mummadi  ^{1  2} ,  Abhisek Banerjee  ^{1  2} ,  Naveen Kumar Dhondi  ^{1  2} ,  James Hennan  ^{1  2} ,  Veena Subray  ^{1  2} ,  Ramya Jayaram  ^{1  2} ,  Nagendra Rajugowda  ^{1  2} ,  Kommuri Umamaheshwar Reddy  ^{1  2} ,  Duraimurugan Kumaraguru  ^{1  2} ,  Umasankar Mandal  ^{1  2} ,  Dasthagiri Beldona  ^{1  2} ,  Ashok Kumar Adisechen  ^{1  2} ,  Navnath Yadav  ^{1  2} ,  Jayakumar Warrier  ^{1  2} ,  James A Johnson  ^{1  2} ,  Harinath Sale  ^{1  2} ,  Siva Prasad Putlur  ^{1  2} ,  Ajay Saxena  ^{1  2} ,  Anjaneya Chimalakonda  ^{1  2} ,  Sandhya Mandlekar  ^{1  2} ,  MaryLee Conder  ^{1  2} ,  Dezhi Xing  ^{1  2} ,  Arun Kumar Gupta  ^{1  2} ,  Anuradha Gupta  ^{1  2} ,  Richard Rampulla  ^{1  2} ,  Arvind Mathur  ^{1  2} ,  Paul Levesque  ^{1  2} ,  Ruth R Wexler  ^{1  2} ,  Heather J Finlay  ^{1  2}